These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 16837126

  • 1. Alfuzosin (10 mg) does not affect blood pressure in young healthy men.
    Mondaini N, Giubilei G, Ungar A, Gontero P, Cai T, Gavazzi A, Bartoletti R, Geppetti P, Carini M.
    Eur Urol; 2006 Dec; 50(6):1292-6; discussion 1297-8. PubMed ID: 16837126
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J.
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [Abstract] [Full Text] [Related]

  • 3. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC, Fiske K, Lyne A.
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [Abstract] [Full Text] [Related]

  • 4. Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study.
    Pedro RN, Hinck B, Hendlin K, Feia K, Canales BK, Monga M.
    J Urol; 2008 Jun; 179(6):2244-7; discussion 2247. PubMed ID: 18423747
    [Abstract] [Full Text] [Related]

  • 5. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
    Rosen R, Seftel A, Roehrborn CG.
    Int J Impot Res; 2007 Jun; 19(5):480-5. PubMed ID: 17717526
    [Abstract] [Full Text] [Related]

  • 6. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects.
    Giuliano F, Kaplan SA, Cabanis MJ, Astruc B.
    Urology; 2006 Jun; 67(6):1199-204. PubMed ID: 16765179
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM, Klarskov P.
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [Abstract] [Full Text] [Related]

  • 8. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG.
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones.
    Agrawal M, Gupta M, Gupta A, Agrawal A, Sarkari A, Lavania P.
    Urology; 2009 Apr; 73(4):706-9. PubMed ID: 19193417
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
    Schulman CC, De Sy W, Vandendris M, Tomas M, Santoni JP.
    Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794
    [Abstract] [Full Text] [Related]

  • 16. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M, ALF-ONE Study Group.
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [Abstract] [Full Text] [Related]

  • 17. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
    Roehrborn CG.
    Prostate Cancer Prostatic Dis; 2006 Apr; 9(2):121-5. PubMed ID: 16304557
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.